APA (7th ed.) Citation

Cabrera‐Perez, J. S., Eigenmann, P., & Akenroye, A. (2024). Editorial comment on "Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long‐term safety (TATE study)". Pediatric Allergy & Immunology, 35(4), 1. https://doi.org/10.1111/pai.14128

Chicago Style (17th ed.) Citation

Cabrera‐Perez, Javier S., Philippe Eigenmann, and Ayobami Akenroye. "Editorial Comment on "Benralizumab in Children with Severe Eosinophilic Asthma: Pharmacokinetics and Long‐term Safety (TATE Study)"." Pediatric Allergy & Immunology 35, no. 4 (2024): 1. https://doi.org/10.1111/pai.14128.

MLA (9th ed.) Citation

Cabrera‐Perez, Javier S., et al. "Editorial Comment on "Benralizumab in Children with Severe Eosinophilic Asthma: Pharmacokinetics and Long‐term Safety (TATE Study)"." Pediatric Allergy & Immunology, vol. 35, no. 4, 2024, p. 1, https://doi.org/10.1111/pai.14128.